Vizgen | $48,000,000 | (Jan 9, 2026)
Corsera Health | $80,000,000 | (Jan 9, 2026)
Oasys | $4,600,000 | (Jan 9, 2026) Certified by Founder
Lodge
AlgoTx
start up
France
- Suresnes, Ile-de-France
- 15/03/2023
- Series B
- $21,157,000
AlgoTx develops novel solutions for complex pain. Our lead program, ATX01, targets highly prevalent Chemotherapy-Induced Peripheral Neuropathy and the orphan disease erythromelalgia.
- Industry Biotechnology Research
- Website https://www.linkedin.com/company/algotx/about/
- LinkedIn https://www.linkedin.com/company/algotx/
Poplar Therapeutics | $50,000,000 | (Jan 9, 2026)
Carna Health | $8,000,000 | (Jan 9, 2026)
Alveus Therapeutics Inc | $160,000,000 | (Jan 9, 2026)
AgileRL | $7,500,000 | (Jan 9, 2026)
Soley Therapeutics | $200,000,000 | (Jan 9, 2026)
SpangleAI | $15,000,000 | (Jan 9, 2026)
Presto Phoenix, Inc. | $10,000,000 | (Jan 9, 2026)
CHAMP | $55,000,000 | (Jan 7, 2026)
Lemon Slice | $10,500,000 | (Jan 7, 2026)